Vimta Labs Limited

NSEI:VIMTALABS Stock Report

Market Cap: ₹19.8b

Vimta Labs Valuation

Is VIMTALABS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VIMTALABS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: VIMTALABS (₹884.9) is trading above our estimate of fair value (₹177.73)

Significantly Below Fair Value: VIMTALABS is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VIMTALABS?

Key metric: As VIMTALABS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for VIMTALABS. This is calculated by dividing VIMTALABS's market cap by their current earnings.
What is VIMTALABS's PE Ratio?
PE Ratio39.9x
Earnings₹493.32m
Market Cap₹19.82b

Price to Earnings Ratio vs Peers

How does VIMTALABS's PE Ratio compare to its peers?

The above table shows the PE ratio for VIMTALABS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average50.8x
544184 Borosil Scientific
55.8xn/a₹16.1b
TARSONS Tarsons Products
63.3x27.7%₹21.5b
WINDLAS Windlas Biotech
35.6xn/a₹21.2b
INNOVACAP Innova Captab
48.6x29.7%₹58.3b
VIMTALABS Vimta Labs
39.9xn/a₹19.8b

Price-To-Earnings vs Peers: VIMTALABS is good value based on its Price-To-Earnings Ratio (39.9x) compared to the peer average (50.8x).

Price to Earnings Ratio vs Industry

How does VIMTALABS's PE Ratio compare vs other companies in the Asian Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
VIMTALABS 39.9xIndustry Avg. 32.2xNo. of Companies6PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: VIMTALABS is expensive based on its Price-To-Earnings Ratio (39.9x) compared to the Asian Life Sciences industry average (32.2x).

Price to Earnings Ratio vs Fair Ratio

What is VIMTALABS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VIMTALABS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio39.9x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate VIMTALABS's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Vivimed Labs

₹410.4m

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India.

VIVIMEDLAB

₹4.95

7D

0%

1Y

-45.9%

Sanofi India

₹142.5b

Manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally.

SANOFI

₹6,197.45

7D

0.8%

1Y

-23.0%

Novartis India

₹26.1b

Operates as a healthcare company in India.

500672

₹1,058.30

7D

3.5%

1Y

52.4%